Celltrion, Inc. is a Korea-based company principally engaged in the biotechnology business. The Company operates in two business segments: biosimilars segment and new biopharmaceutical development segment. Its biosimilars segment develops and manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer and others. Its new biopharmaceutical development segment engages in the development of biopharmaceuticals, such as monoclonal antibodies against rabies and breast cancers, pandemics and seasonal influenza viruses, through co-development with multinational pharmaceutical and biotechnology companies.